^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Colorectal Cancer
    Drug:Sutent (sunitinib) (c-KIT inhibitor, VEGFR inhibitor, PDGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    ...for the treatment of advanced CRC include sunitinib plus FOLFIRI, cetuximab plus brivanib, erlotinib plus bevacizumab, cediranib plus FOLFOX/CAPEOX, and atezolizumab plus cobimetinib. These regimens are not recommended for the treatment of patients with CRC.
    Secondary therapy:
    FOLFIRI
    Evidence Level:
    Resistant: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Colorectal cancer...the panel recommends against the use of mitomycin, alfa-interferon, taxanes, methotrexate, pemetrexed, sunitinib, sorafenib, erlotinib, or gemcitabine, either as single agents or in combination, as therapy in patients exhibiting disease progression after treatment with standard therapies.